INFUSE[®] BONEGRAFT



SUMMARY OF INDICATIONS

SPINE


ALIF - with Medtronic titanium threaded interbody device. OLIF - with Medtronic PERIMETER[™] or CLYDESDALE[™] interbody device.

TRAUMA

Acute open tibial fractures with IM nail fixation.

DENTAL

Sinus augmentation and localized alveolar ridge augmentation for defects associated with extraction sockets.




PRODUCT COMPOSITION, HANDLING & STERILITY

1	 1.5mg/cc rhBMP-2 98% pure, freeze dried Type I bovine collagen sponge (ACS) Sterile water
2	 Absorbable collagen sponge (ACS) provides localized protein delivery ACS provides scaffold for new bone ingrowth
3	 rhBMP-2: Filter sterilization, maintains bioactivity level ACS: Device-level sterility (SAL 10⁻⁶)

PERFORMANCE

SPINE



- 94.5% fusion rate at 24
 months, compared to 88.7%
 with autograft alone¹
- 55% improved in Oswestry scores on average¹
- Reduced hospital stay, less
 blood loss and less OR time¹
- 98% fusion success at 6 year follow-up²

TRAUMA



- Significantly reduced secondary surgical interventions by 41%³
- Significantly reduced nonunion rate by 29%³
- Significantly reduced infection rate in severe fractures by 44%³


DENTAL



- Average of 10.41mm of new bone generated in implant sites with less than 4mm native bone⁵
- Histology demonstrates normal mature 100% viable bone⁵
- Equivalent implant survival rates vs. autogenous bone graft⁴

MODE OF ACTION

Differentiation



Osteoblast

New Bone Formation

INFUSE[®] rhBMP-2 is an osteoinductive protein that results in the induction of new bone tissue at the site of implantation.

Surgical implantation and retention of rhBMP-2 at the treatment site is facilitated by the ACS matrix.

rhBMP-2 binds to receptors on the surface of mesenchymal stem cells (MSCs) and causes cells to differentiate into bone forming cells (osteoblasts).

Medtronic

Mesenchymal Cell + rhBMP-2 Molecule

PRODUCTS

XX Small 1.05mg Vial rhBMP-2 0.7ml (cc) Graft Volume	X Small 2x 1.05mg Vials rhBMP-2 1.4ml (cc) Graft Volume	Small 4.2mg Vial rhBMP-2 2.8ml (cc) Graft Volume
Medium 2x 4.2mg Vials	Large 12mg Vial rhBMP-2	
rhBMP-2	8.0ml (cc) Graft	12mg Vial rhBMP-2 8.0ml (cc) Graft

REFERENCES

- 1. Burkus et al. Anterior Lumbar Interbody Fusion Using rhBMP-2 With Tapered Interbody Cages. Journal of Spinal Disorders and Techniques. 2002, Vol. 15, no 5. pp. 337-349.
- 2. Burkus JK, Gornet MF, et al. Six-Year Outcomes of Anterior Lumbar Interbody Arthrodesis with Use of Interbody Fusion Cages and Recombinant Human Bone Morphogenetic Protein-2. J Bone Joint Surg Am. 2009; 91:1181-9
- US Food and Drug Administration. Summary of Safety and Effectiveness INFUSE Bone Graft (P000054) <u>http://www.fda.gov/cdrh/pdf/p000054b.pdf</u>
- US Food and Drug Administration. Summary of Safety and Effectiveness INFUSE Bone Graft (P000053) <u>http://www.fda.gov/cdrh/pdf/p000053b.pdf</u>
- Triplett, et al. Pivotal, Randomized, Parrallel Evaluation of Recombinant Human Bone Morphogenetic Protein-2/ Absorbable Collagen Sponge and Autgenous Bone Graft for Maxillary Sinus Floor Augmentation. J Oral Maxillofac Surg. 67:1947-60, 2009

The product systems referenced in this presentation may incorporate technology developed by Gary K. Michelson, M.D.



THANK YOU

